Atrion (NASDAQ:ATRI) Downgraded by StockNews.com

StockNews.com cut shares of Atrion (NASDAQ:ATRI) from a hold rating to a sell rating in a report published on Wednesday.

Atrion Stock Performance

ATRI stock opened at $414.95 on Wednesday. Atrion has a one year low of $274.98 and a one year high of $613.16. The firm’s fifty day moving average is $411.60 and its 200 day moving average is $365.71. The firm has a market cap of $730.31 million, a PE ratio of 37.62 and a beta of 0.62.

Atrion (NASDAQ:ATRI) last announced its earnings results on Thursday, February 29th. The medical instruments supplier reported $3.65 earnings per share for the quarter. Atrion had a return on equity of 8.07% and a net margin of 11.46%. The business had revenue of $43.58 million during the quarter.

Atrion Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 15th were given a $2.20 dividend. The ex-dividend date was Thursday, March 14th. This represents a $8.80 annualized dividend and a dividend yield of 2.12%. Atrion’s dividend payout ratio (DPR) is 79.78%.

Institutional Trading of Atrion

Institutional investors have recently made changes to their positions in the company. Exchange Traded Concepts LLC purchased a new position in shares of Atrion in the third quarter worth about $333,000. Bank of New York Mellon Corp lifted its stake in Atrion by 2.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 10,006 shares of the medical instruments supplier’s stock worth $4,134,000 after purchasing an additional 194 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Atrion by 2.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 10,385 shares of the medical instruments supplier’s stock worth $4,291,000 after purchasing an additional 243 shares during the last quarter. WINTON GROUP Ltd purchased a new stake in shares of Atrion in the third quarter valued at approximately $208,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Atrion in the fourth quarter valued at approximately $108,000. 66.19% of the stock is owned by institutional investors and hedge funds.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.